In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

India is close to approving a genetically edited variety of mustard, which offers better nutrition and disease resistance ...

Transgene Biote Share: compare Transgene Biote with up to two competing stocks only on Moneycontrol. Use our stock comparison tool to check price, market cap, returns & more ...

D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products ...

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition ...

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.